{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T23:23:32Z","timestamp":1785713012627,"version":"3.56.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,3,29]],"date-time":"2011-03-29T00:00:00Z","timestamp":1301356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,3,29]],"date-time":"2011-03-29T00:00:00Z","timestamp":1301356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1038\/pcan.2011.11","type":"journal-article","created":{"date-parts":[[2011,3,29]],"date-time":"2011-03-29T10:14:50Z","timestamp":1301393690000},"page":"184-190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide"],"prefix":"10.1038","volume":"14","author":[{"given":"P","family":"Iversen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Karup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"van der Meulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L B","family":"Tank\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Huhtaniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,3,29]]},"reference":[{"key":"BFpcan201111_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1517\/14656566.9.2.211","volume":"9","author":"EA Singer","year":"2008","unstructured":"Singer EA, Golijanin DJ, Miyamoto H, Messing EM . Androgen deprivation therapy for prostate cancer. Expert Opin Pharmacother 2008; 9: 211\u2013228.","journal-title":"Expert Opin Pharmacother"},{"key":"BFpcan201111_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jsbmb.2004.10.005","volume":"92","author":"T Tammela","year":"2004","unstructured":"Tammela T . Endocrine treatment of prostate cancer. J Steroid Biochem Mol Biol 2004; 92: 287\u2013295.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"BFpcan201111_CR3","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.urology.2007.12.070","volume":"71","author":"H Van Poppel","year":"2008","unstructured":"Van Poppel H, Nilsson S . Testosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology 2008; 71: 1001\u20131006.","journal-title":"Urology"},{"key":"BFpcan201111_CR4","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.urology.2004.07.033","volume":"64","author":"NR Zinner","year":"2004","unstructured":"Zinner NR, Bidair M, Centeno A, Tomera K . Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 and 10.8\u2009mg: results of a randomized open-label trial. Urology 2004; 64: 1177\u20131181.","journal-title":"Urology"},{"key":"BFpcan201111_CR5","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1016\/j.juro.2008.07.033","volume":"180","author":"M Gittelman","year":"2008","unstructured":"Gittelman M, Pommerville PJ, Persson BE, Jensen JK, Kold Olesen T . A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol 2008; 180: 1986\u20131992.","journal-title":"J Urol"},{"key":"BFpcan201111_CR6","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.eururo.2008.04.065","volume":"54","author":"H Van Poppel","year":"2008","unstructured":"Van Poppel H, Tombal B, de la Rosette JJ, Persson B-E, Jensen J-K, Kold Olesen T . Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker\u2014results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol 2008; 54: 805\u2013815.","journal-title":"Eur Urol"},{"key":"BFpcan201111_CR7","first-page":"263","volume":"1","author":"AC Spetz","year":"2003","unstructured":"Spetz AC, Zetterlund E-L, Varenhorst E, Hammar M . Incidence and management of hot flashes in prostate cancer. J Support Oncol 2003; 1: 263\u2013273.","journal-title":"J Support Oncol"},{"key":"BFpcan201111_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3816\/SCT.2006.n.029","volume":"4","author":"TJ Alekshun","year":"2006","unstructured":"Alekshun TJ, Patterson SG . Management of hot flashes in men with prostate cancer being treated with androgen deprivation therapy. Supportive Cancer Ther 2006; 4: 30\u201337.","journal-title":"Supportive Cancer Ther"},{"key":"BFpcan201111_CR9","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1046\/j.1464-4096.2001.01761.x","volume":"89","author":"C Kouriefs","year":"2002","unstructured":"Kouriefs C, Georgiou M, Ravi R . Hot flushes and prostate cancer: pathogenesis and treatment. BJU Int 2002; 89: 379\u2013383.","journal-title":"BJU Int"},{"key":"BFpcan201111_CR10","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jama.294.2.238","volume":"294","author":"N Sharifi","year":"2005","unstructured":"Sharifi N, Gulley JL, Dahut WL . Androgen deprivation therapy for prostate cancer. JAMA 2005; 294: 238\u2013244.","journal-title":"JAMA"},{"key":"BFpcan201111_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s11934-005-0009-2","volume":"6","author":"AC Chen","year":"2005","unstructured":"Chen AC, Petrylak DP . Complications of androgen-deprivation therapy. Curr Urol Rep 2005; 6: 210\u2013216.","journal-title":"Curr Urol Rep"},{"key":"BFpcan201111_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/00042307-200405000-00007","volume":"14","author":"JM Holzbeierlein","year":"2004","unstructured":"Holzbeierlein JM, McLaughlin MD, Thrasher JB . Complications of androgen deprivation therapy for prostate cancer. Curr Opin Urol 2004; 14: 177\u2013183.","journal-title":"Curr Opin Urol"},{"key":"BFpcan201111_CR13","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/S0022-5347(17)32530-2","volume":"152","author":"P Karling","year":"1994","unstructured":"Karling P, Hammar M, Varenhorst E . Prevalence and duration of vasomotor symptoms after surgical or medical castration in men with prostatic carcinoma. J Urol 1994; 152: 1170\u20131173.","journal-title":"J Urol"},{"key":"BFpcan201111_CR14","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1097\/00005392-200204000-00021","volume":"167","author":"J Trachtenberg","year":"2002","unstructured":"Trachtenberg J, Gittleman M, Steidle C, Barzell W, Friedel W, Pessis D, Abarelix Study Group et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002; 167: 1670\u20131674.","journal-title":"J Urol"},{"key":"BFpcan201111_CR15","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/S0090-4295(01)01342-5","volume":"58","author":"D McLeod","year":"2001","unstructured":"McLeod D, Zinner N, Tomera K, Gleason D, Fotheringham N, Campion M, Abarelix Study Group et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001; 58: 756\u2013761.","journal-title":"Urology"},{"key":"BFpcan201111_CR16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2217\/14796694.2.6.677","volume":"2","author":"F Debruyne","year":"2006","unstructured":"Debruyne F, Bhat G, Garnick MB . Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer. Future Oncol 2006; 2: 677\u2013696.","journal-title":"Future Oncol"},{"key":"BFpcan201111_CR17","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","volume":"102","author":"L Klotz","year":"2008","unstructured":"Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008; 102: 1531\u20131538.","journal-title":"BJU Int"},{"key":"BFpcan201111_CR18","first-page":"5063","volume":"17","author":"PJ Pommerville","year":"2010","unstructured":"Pommerville PJ, de Boer JG . GnRH antagonists in the treatment of advanced prostate cancer. Can J Urol 2010; 17: 5063\u20135070.","journal-title":"Can J Urol"},{"key":"BFpcan201111_CR19","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1200\/JCO.2001.19.23.4280","volume":"19","author":"JA Sloan","year":"2001","unstructured":"Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H . Methodologic lessons learned from hot flash\/flush studies. J Clin Oncol 2001; 19: 4280\u20134290.","journal-title":"J Clin Oncol"},{"key":"BFpcan201111_CR20","first-page":"155","volume":"14","author":"S Quella","year":"1994","unstructured":"Quella S, Loprinzi CL, Dosee AM . A qualitative approach to defining hot flash\/flushes in men. Urol Nurs 1994; 14: 155\u2013158.","journal-title":"Urol Nurs"},{"key":"BFpcan201111_CR21","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1089\/jwh.2006.0033","volume":"16","author":"S Appling","year":"2007","unstructured":"Appling S, Paez K, Allen J . Ethnicity and vasomotor symptoms in postmenopausal women. J Womens Health (Larchmt) 2007; 16: 1130\u20131138.","journal-title":"J Womens Health (Larchmt)"},{"key":"BFpcan201111_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2217\/17455057.5.2.127","volume":"5","author":"R Green","year":"2009","unstructured":"Green R, Santoro N . Menopausal symptoms and ethnicity: the Study of Women's Health Across the Nation. Womens Health (Lond Engl) 2009; 5: 127\u2013133.","journal-title":"Womens Health (Lond Engl)"},{"key":"BFpcan201111_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1093\/aje\/kwm244","volume":"167","author":"RC Thurston","year":"2008","unstructured":"Thurston RC, Sowers MR, Chang Y, Sternfeld B, Gold EB, Johnston JM et al. Adiposity and reporting of vasomotor symptoms among midlife women: the study of women\u2032s health across the nation. Am J Epidemiol 2008; 167: 78\u201385.","journal-title":"Am J Epidemiol"},{"key":"BFpcan201111_CR24","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1210\/jc.2007-1972","volume":"93","author":"FC Wu","year":"2008","unstructured":"Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O\u2019Neill TW et al. European Male Aging Study Group. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 2008; 93: 2737\u20132745.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFpcan201111_CR25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/01443610701405812","volume":"27","author":"A Badawy","year":"2007","unstructured":"Badawy A, State O, Sherief S . Can thyroid dysfunction explicate severe menopausal symptoms? J Obstet Gynaecol 2007; 27: 503\u2013505.","journal-title":"J Obstet Gynaecol"},{"key":"BFpcan201111_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1258\/175404507780456746","volume":"13","author":"EN Pearce","year":"2007","unstructured":"Pearce EN . Thyroid dysfunction in perimenopausal and postmenopausal women. Menopause Int 2007; 13: 8\u201313.","journal-title":"Menopause Int"},{"key":"BFpcan201111_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0378-5122(01)00256-0","volume":"41","author":"I \u00d8verlie","year":"2002","unstructured":"\u00d8verlie I, Moen MH, Holte A, Finset A . Androgens and estrogens in relation to hot flushes during the menopausal transition. Maturitas 2002; 41: 69\u201377.","journal-title":"Maturitas"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/pcan201111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201111","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T21:23:24Z","timestamp":1648675404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pcan201111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,29]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["BFpcan201111"],"URL":"https:\/\/doi.org\/10.1038\/pcan.2011.11","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,29]]},"assertion":[{"value":"22 December 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Karup, Dr van der Meulen and Dr Tank\u00f3 are full-time employees of Ferring Pharmaceuticals. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}